Artelo Biosciences, Inc. (ARTL) Stock Price & Analysis
Artelo Biosciences, Inc. (ARTL) rose 0.00% to USD 1.33 as of June 10, 2026 at 04:39 UTC, according to Nexqual real-time market data.
ARTL last closed at USD 1.33; the session ranged USD 1.31–1.35 on volume of 179,218 shares. Market capitalization is $4.64M, with a 52-week range of USD 1.19–85.8 (NCM). Source: Nexqual, June 10, 2026 at 04:39 UTC.
Key Statistics (as of June 10, 2026 at 04:39 UTC)
| Price | USD 1.33 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.33 |
| Open | USD 1.34 |
| Day Range | USD 1.31 – 1.35 |
| 52-Week Range | USD 1.19 – 85.8 |
| Volume | 179,218 shares |
| Market Cap | $4.64M |
| Exchange | NCM |
Technical Analysis (ARTL)
Nexqual's technical model rates ARTL "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.66 (oversold) |
| vs SMA50 | Below (USD 3.71) |
| MACD | -0.56 (negative) |
Analyst Ratings (ARTL)
Wall Street analysts rate ARTL "None", per Nexqual as of June 10, 2026 at 04:39 UTC.
| Consensus Rating | None |
|---|
Earnings (ARTL)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.12 vs est -4.71 ▲ beat |
| 2025-06-30 | USD -16.83 vs est -12.57 ▼ miss |
| 2025-03-31 | USD -12.96 vs est -2.34 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:39 UTC.
Financials & Fundamentals (ARTL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -367.69% |
| Debt / Equity | 10.78 |
| Current Ratio | 1.79 |
| Total Cash | $10.27M |
| Total Debt | $719,000 |
| Free Cash Flow | $-3.29M |
Source: Nexqual, June 10, 2026 at 04:39 UTC.
Financial Health Score (ARTL)
Nexqual rates Artelo Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -368%, ROA -91.3% |
Ownership (ARTL)
| Insider Ownership | +2.47% |
|---|---|
| Institutional Ownership | +8.10% |
| Shares Outstanding | 3.49M |
| Float | 2.12M |
| Short % of Float | +6.28% |
Source: Nexqual, June 10, 2026 at 04:39 UTC.
Leadership (ARTL)
Artelo Biosciences, Inc. is led by Gregory D. Gorgas (age 62), President, CEO, Secretary & Director, per Nexqual as of June 10, 2026 at 04:39 UTC.
| President, CEO, Secretary & Director | Gregory D. Gorgas (age 62) |
|---|---|
| Senior VP & Chief Scientific Officer | Andrew Yates |
| Senior Vice President of Finance | Jason H. Baybutt (age 53) |
Major Backers & Investors (ARTL)
Notable institutional backers of Artelo Biosciences, Inc. include Kathmere Capital Management, Llc, Jane Street Group, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 04:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kathmere Capital Management, Llc | 0.38% |
| Jane Street Group, LLC | 0.38% |
| Fidelity | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.42% |
Source: Nexqual, June 10, 2026 at 04:39 UTC.
From Artelo Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- These data are aligned with safety outcomes observed in Phase 1 of CAReS, supporting ART27.13's overall favorable tolerability and acceptable safety profile.   Our second in-licensed patented program is being advanced from our platform of small-molecule inhibitors of FABPs, notably FABP5.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENVB | Enveric Biosciences, Inc. | USD 1.6 | ▼ 11.11% |
| ITRMF | Iterum Therapeutics plc | USD 0.05 | ▲ 0% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| DCOY | Decoy Therapeutics Inc. | USD 5.51 | ▼ 16.64% |
| RKTO | Rocket One Inc. | USD 1.28 | ▼ 15.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:39 UTC. This page is informational and not investment advice.